Blueprint
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For
period ending 12 November
2018
GlaxoSmithKline plc
(Name
of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or
will
file annual reports under cover Form 20-F or Form
40-F
Form
20-F x Form 40-F
--
Indicate
by check mark whether the registrant by furnishing the
information
contained in this Form is also thereby furnishing the
information
to the Commission pursuant to Rule 12g3-2(b) under the
Securities
Exchange Act of 1934.
Yes
No x
GlaxoSmithKline
plc
Blocklisting Application
Application has been made to the Financial Conduct Authority and
the London Stock Exchange Plc for a total of 5,575,000 Ordinary
shares of 25p each ('Shares') to be admitted to the Official
List.
These Shares are being reserved under block listings and will be
issued as a result of the award of Shares pursuant to the following
schemes:
|
Scheme
|
Shares
|
|
GlaxoSmithKline
plc 2009 Deferred Annual Bonus Plan
|
575,000
|
|
GlaxoSmithKline
plc Sharesave plan 2012
|
5,000,000
|
When issued, these shares will rank pari passu with the existing
Shares.
Victoria Whyte
Company Secretary
12 November 2018
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: November
12, 2018
|
|
|
|
|
|
|
By: VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|